TFRC and hepatocellular carcinoma: Modulation of OGT activity could potentially sensitize resistant HCC cells to ferroptosis-inducing therapies, while the identification of specific O-GlcNAcylation sites on ferroptosis regulators like TFRC provides opportunities for developing targeted small-molecule inhibitors that selectively disrupt these protective modifications.